Erlocip 150mg
Available Dosages
| SKU | 1493 |
|---|---|
| Generic For | Tarceva |
| Strength | 150mg |
| Manufacturer | Cipla |
| Active Ingredient | Erlotinib |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 8.43 | US$ 253.00 | |||
|
|||||
Erlocip 150mg – Affordable Tarceva Alternative for Lung Cancer
Erlotinib is the primary constituent present in the drug Erlocip 150 mg. This complex is a drug which is accustomed to treating non-small cell carcinoma, carcinoma and someother kinds of cancer. It's a reversible amino acid enzyme matterthat acts on the epidermic protein receptor.
What is Erlocip drug used for?
Erlocip 150 mg is used as the first-line treatment of patients with pathological process non-small cell carcinoma. whose tumors have stratum protein receptor coding DNA nineteen deletions or coding DNA twenty-one (L858R) substitution mutations as detected by FDA. The upkeep treatment of patients with domestically advanced or pathological process non-small cell carcinoma whose illness has not progressed once four cycles of platinum-based first-line therapy. The treatment of patients with domestically advanced or pathological process non-small cell carcinoma once thefailure of a minimum of one previous therapy program.
How does Erlocip drug works?
Erlotinib is associated in nursing epidermic protein receptor matter (EGFR inhibitor). The drug follows Iressa (gefitinib) that was the primary drug of this sort. Erlotinib specifically targets the epidermic protein receptor (EGFR) amino acid enzyme, that is remarkably expressed and sometimes mutated in numerous styles of cancer. It binds in a very reversible fashion to the nucleotide (ATP) binding web site of the receptor. For the signal to be transmitted, 2 EGFR molecules got to move to create a homodimer. These then use the molecule of adenosine triphosphate to trans-phosphorylate one another on amino acid residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding macromolecules to EGFR to assemble protein complexes that convert signal cascades to the nucleus or activate alternative cellular organic chemistry processes. Once erlotinib binds to EGFR, theformation of phosphotyrosine residues in EGFR isn't doable, and also, the signal cascades don't seem to be initiated.
What medication interact with Erlocip?
Avoid consuming this drug along with bumetanide, furosemide, hydrochlorothiazide, gentamycin, tobramycin, amphotericin B, ibuprofen, tacrolimus, vancomycin.While using this medication, you ought to not be treated with alternative bisphosphonates, together with alternative brands of Erlocip accustomed forestall or treat bone loss (osteoporosis).
Always consult your physician and pharmacist if you are taking any other medicines, which are not prescribed such as herbal tonics, supplements, and medications
When should Erlocip drug not be used?
- Erlocip 150 mg should not be used if the patient is allergic to the composition of this drug
- This medication should not be prescribed to children below ten years of age
- Please consult your doctor before taking this medicine if you are planning to conceive or you are lactating women
What are the side effects of the Erlocip drug?
Some of the most common side effects related to the consumption of this drug are inflammation, itching, rashes, weight gain, profuse sweating, vertigo, problems in breathing, suffocation, dark urine, increased heart palpitation, cough, cold, nausea, vomiting, puffy face and neck, dizziness, change of vision, dull skin, and paralysis.
How should Erlocip drug be used?
This medication should be utilized consumed as a whole tablet with sufficient amount of water. Swallow this capsule and do not chew or crush the pill. When you buy this drug online from our website Premiumrxdrugs, make sure to keep a note of all the instructions and precautions to be followed. If you still have any query do consult your physician and do as instructed.
How long should Erlocip drug be used?
Use this medication as per the prescription of your doctor. The initial dose of this medication for adults is 3 to 4 times every day. Do not stop taking this medicine without the consent of your doctor even if your symptoms are subsided.
Missed dose of Erlocip drug:
If you have missed a dose take is as soon as you remember. Please avoid taking any dose if it is already the time to take the next dose.
How should Erlocip drug be stored?
Store this medication in a cool, dry place and out of the reach of your children and pets. Medicines must not be used past the expiry date. Dispose of the wrapper properly. Do not refrigerate the drug.
What is Erlotinib and what condition does it treat?
Erlotinib is a targeted cancer therapy medication, marketed under the brand name Erlocip 150mg, primarily prescribed for treating non-small cell lung cancer (NSCLC) and pancreatic cancer. This tyrosine kinase inhibitor works by blocking specific proteins that promote cancer cell growth and division. Erlocip 150mg is particularly effective in patients whose tumours have specific EGFR (epidermal growth factor receptor) mutations. Oncologists also prescribe this anticancer drug as maintenance therapy after initial chemotherapy or when cancer has spread to other body parts. The medicine belongs to a class called EGFR inhibitors, representing a precision medicine approach to cancer treatment.
How does Erlotinib work in the body?
Erlotinib functions as a selective EGFR tyrosine kinase inhibitor that targets cancer cells at the molecular level. The active ingredient in Erlocip 150mg binds to the epidermal growth factor receptor on cancer cells, preventing signals that tell these cells to multiply and survive. By blocking this protein pathway, the anticancer medication essentially starves tumour cells of growth signals they need to thrive. Unlike traditional chemotherapy that attacks all rapidly dividing cells, this targeted cancer therapy specifically focuses on cells with EGFR mutations, reducing damage to healthy tissue. This precision mechanism makes Erlocip 150mg particularly valuable in personalized oncology treatment plans.
How long does Erlocip 150mg take to work?
Erlocip 150mg begins working at the cellular level within hours of ingestion, with peak blood concentrations of Erlotinib reached approximately four hours after taking the dose. However, measurable clinical responses in non-small cell lung cancer typically become evident after several weeks of continuous daily therapy. Most oncologists evaluate treatment effectiveness through imaging scans after 6-8 weeks of taking this targeted cancer medication. Some patients notice symptom improvements such as reduced coughing or breathing difficulties within the first month. Response times vary significantly based on cancer type, mutation status, disease stage, and individual patient factors, making regular monitoring essential during Erlocip 150mg treatment.
When and how should I take Erlocip 150mg?
Take Erlocip 150mg once daily on an empty stomach, at least one hour before eating or two hours after finishing a meal. Swallow the tablet whole with water without crushing or breaking it. Maintaining consistent timing—such as taking your Erlotinib dose at the same time each morning—helps maintain steady medication levels in your bloodstream. Food significantly reduces absorption of this anticancer medication, potentially decreasing its effectiveness against non-small cell lung cancer. If you miss a dose and it's more than 12 hours until your next scheduled dose, take it immediately; otherwise, skip it and resume your normal schedule. Always follow your oncologist's specific instructions.
Is Erlocip 150mg safe for long-term use?
Erlocip 150mg is designed for ongoing, long-term use in managing non-small cell lung cancer and pancreatic cancer, with many patients continuing this targeted therapy for months or years. Clinical trials have demonstrated that extended Erlotinib treatment can provide sustained cancer control when the medication remains effective. Your oncology team will conduct regular monitoring including blood tests, liver function assessments, and imaging scans to ensure the anticancer drug continues working safely. While long-term use may increase cumulative side effect risks such as skin changes or digestive issues, many patients tolerate extended Erlocip 150mg therapy well. Treatment duration depends on how your cancer responds and your overall tolerance to the medication.
Can I take Erlocip 150mg with other medicines?
Erlocip 150mg can interact with numerous medications, requiring careful management by your healthcare team. This EGFR inhibitor is particularly affected by drugs that change stomach acidity—antacids, proton pump inhibitors like omeprazole, and H2 blockers may reduce Erlotinib absorption. Blood thinners such as warfarin may require dose adjustments when combined with this anticancer medication. Certain antibiotics, antifungals, and seizure medications can either increase or decrease Erlocip 150mg levels in your bloodstream. St. John's Wort and some herbal supplements should be avoided. Always provide your oncologist with a complete list of prescription medicines, over-the-counter drugs, and supplements before starting this targeted cancer therapy.
How does Erlocip 150mg compare to similar medicines in its class?
Erlocip 150mg belongs to the EGFR tyrosine kinase inhibitor class alongside gefitinib (Iressa) and afatinib (Gilotrif). While all these targeted cancer therapies block EGFR signaling in non-small cell lung cancer, Erlotinib offers several advantages including once-daily dosing and extensive clinical evidence supporting its effectiveness. Compared to gefitinib, Erlocip 150mg demonstrates similar efficacy but may have different side effect profiles in individual patients. Afatinib irreversibly binds to EGFR while Erlotinib binds reversibly, representing a key pharmacological difference. Newer-generation EGFR inhibitors like osimertinib target specific resistance mutations, but Erlocip 150mg remains a first-line standard treatment option with proven long-term outcomes and competitive pricing.
Is the generic Erlotinib as effective as branded versions?
Generic Erlotinib formulations like Erlocip 150mg contain the identical active pharmaceutical ingredient as the original branded version Tarceva, delivering equivalent therapeutic effectiveness against non-small cell lung cancer. Regulatory authorities in the USA, UK, Canada, and Australia require generic anticancer medications to demonstrate bioequivalence—meaning they perform identically in the body. Erlocip 150mg must meet the same stringent manufacturing standards and purity requirements as branded EGFR inhibitors. The primary difference lies in pricing, with generic Erlotinib typically costing significantly less while providing the same cancer-fighting benefits. Many oncologists now preferentially prescribe generic versions to reduce patient financial burden without compromising treatment outcomes.
Why do patients choose PremiumRxDrugs for Erlocip 150mg?
Patients consistently select PremiumRxDrugs for their Erlotinib prescriptions due to significant cost savings on this essential anticancer medication compared to local pharmacy prices. The platform guarantees authentic, manufacturer-sourced Erlocip 150mg, eliminating concerns about counterfeit cancer treatments. Convenient features include easy prescription management, straightforward reordering for continuous non-small cell lung cancer therapy, and discreet packaging that protects patient privacy. As a licensed pharmacy operating for over ten years, PremiumRxDrugs has earned trust across the USA, UK, Australia, and Canada by delivering reliable access to targeted cancer therapies. Worldwide shipping with free delivery options makes ongoing EGFR inhibitor treatment more accessible and affordable for long-term cancer management.
What are the common side effects of Erlotinib?
Common side effects of Erlotinib include skin rash (occurring in approximately 75% of patients), diarrhea, loss of appetite, fatigue, and dry skin. Many patients experience acne-like breakouts on the face and chest, which ironically often correlates with better treatment response to this EGFR inhibitor. Digestive issues such as nausea and abdominal discomfort affect many users of this anticancer medication. Eye irritation, mouth sores, and brittle nails are also frequently reported. Most side effects are manageable with supportive care like moisturizers for skin issues and anti-diarrheal medications. Serious but less common reactions include lung problems, liver function changes, and gastrointestinal perforation, requiring immediate medical attention.
Who should avoid taking Erlotinib?
Pregnant women should not take Erlotinib as this EGFR inhibitor can cause serious birth defects and fetal harm; effective contraception is essential during treatment and for one month after stopping. Women who are breastfeeding should avoid this anticancer medication as it may pass into breast milk. Patients with severe liver impairment require careful evaluation before starting Erlotinib therapy. Individuals with a history of gastrointestinal ulceration or diverticular disease face increased perforation risks. Those with known hypersensitivity to Erlotinib or any tablet components should not use this medication. Patients taking certain medications that severely interact with this targeted cancer therapy may need alternative treatments determined by their oncology team.
Login
Sign Up
Login
Sign Up